Tempus‑Personalis Deal: $1.7 B AI‑Driven Leap into Precision Oncology
Tempus’s $1.7B all‑stock buy of Personalis unlocks $20B MRD market, fusing AI diagnostics with liquid biopsy for next‑gen precision oncology.
3 minutes to read
PERSONALIS INC
Personalis Inc. Leads the Charge in Personalized Cancer Treatment with Genomic Innovations
Personalis Inc. is a leading company in genomic sequencing and analytics, driving the development of personalized cancer vaccines and immunotherapies that are transforming cancer treatment and patient care.
2 minutes to read